These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 15935302

  • 1. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.
    Slavcev A, Lácha J, Honsová E, Sajdlová H, Lodererová A, Vitko S, Skibová J, Striz I.
    Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302
    [Abstract] [Full Text] [Related]

  • 2. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA.
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [Abstract] [Full Text] [Related]

  • 3. High serum soluble CD30 does not predict acute rejection in liver transplant patients.
    Matinlauri I, Höckerstedt K, Isoniemi H.
    Transplant Proc; 2006 Dec; 38(10):3601-4. PubMed ID: 17175343
    [Abstract] [Full Text] [Related]

  • 4. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection.
    Ayed K, Abdallah TB, Bardi R, Abderrahim E, Kheder A.
    Transplant Proc; 2006 Sep; 38(7):2300-2. PubMed ID: 16980071
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation.
    Hamer R, Roche L, Smillie D, Harmer A, Mitchell D, Molostvov G, Lam FT, Kashi H, Tan LC, Imray C, Fletcher S, Briggs D, Lowe D, Zehnder D, Higgins R.
    Transpl Immunol; 2010 Aug; 23(4):161-5. PubMed ID: 20600903
    [Abstract] [Full Text] [Related]

  • 8. Soluble CD30 in renal transplant recipients: is it a good biomarker to predict rejection?
    Azarpira N, Aghdaie MH, Malekpour Z.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):31-6. PubMed ID: 20061689
    [Abstract] [Full Text] [Related]

  • 9. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
    Truong DQ, Darwish AA, Gras J, Wieërs G, Cornet A, Robert A, Mourad M, Malaise J, de Ville de Goyet J, Reding R, Latinne D.
    Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
    [Abstract] [Full Text] [Related]

  • 10. Soluble CD30 as a prognostic factor for outcome following renal transplantation.
    Platt RE, Wu KS, Poole K, Newstead CG, Clark B.
    J Clin Pathol; 2009 Jul; 62(7):662-3. PubMed ID: 19561239
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CD30, a marker to detect the high-risk kidney transplant recipients.
    Spiridon C, Nikaein A, Lerman M, Hunt J, Dickerman R, Mack M.
    Clin Transplant; 2008 Jul; 22(6):765-9. PubMed ID: 19040559
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation.
    Kim MS, Kim HJ, Kim SI, Ahn HJ, Ju MK, Kim HJ, Jeon KO, Kim YS.
    Transplantation; 2006 Dec 27; 82(12):1602-5. PubMed ID: 17198243
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
    Vaidya S, Partlow D, Barnes T, Thomas P, Gugliuzza K.
    Clin Transplant; 2006 Dec 27; 20(4):461-4. PubMed ID: 16842522
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
    Rodríguez LM, París SC, Arbeláez M, Cotes JM, Süsal C, Torres Y, García LF.
    Hum Immunol; 2007 Aug 27; 68(8):652-60. PubMed ID: 17678719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.